 |
|
|
| |
Participant and Provider Experiences With Long-Acting Cabotegravir vs Lenacapavir Injections: Results From the CLARITY Study
|
| |
| |
IAS 2026 Rio, Brazil
Katherine L. Nelson,1 Laure Dupont-Benjamin,2 Justine Boles,3 Emilie Elliot,4 Dainielle Fox,1 Apinya Vutikullird,5 Amber Mottola,5
Kim Fletcher,6 Kehui Wang,7 Suryakant Somvanshi,8 Richard Grove,6 Rebecca Borsi,1 Nanlesta Pilgrim,1 Piotr Budnik,3 Jean van Wyk,3 Harmony P. Garges,7 Kimberley Brown1
1ViiV Healthcare, Durham, NC, USA; 2ViiV Healthcare, Rueil-Malmaison, France; 3ViiV Healthcare, London, UK; 4ViiV Healthcare, Madrid, Spain; 5Ark Clinical Research, Long Beach, CA, USA; 6GSK, London, UK; 7GSK, Durham, NC, USA; 8GSK, GCC, Bengaluru, India
|
| |
|
|
|
|
|
